keyword
MENU ▼
Read by QxMD icon Read
search

Metastatic colorectal cancer

keyword
https://www.readbyqxmd.com/read/28098895/microrna-133b-is-regulated-by-tap63-while-no-gene-mutation-is-present-in-colorectal-cancer
#1
Yifei Chen, Yi Zhang, Jianhuai He, Ying Fu, Changwei Lin, Xiaorong Li
Downregulation of miR-133b has been reported in multiple types of malignancies including colorectal cancer (CRC). We previously confirmed that TAp63 actively translates microRNA-133b (miR-133b) transcripts. While the presence of miRNA mutations have frequently been described in CRC, most CRCs do not show any variation in the miR‑133b coding sequence. Therefore, it is important to elucidate the relationship between TAp63 and miR-133b, and identify other mediators of miR-133b downregulation in CRC. The expression of TAp63 was detected by RT-qPCR, western blotting, immunohistochemistry (IHC) and densitometric analysis using Image-Pro Plus 6...
January 16, 2017: Oncology Reports
https://www.readbyqxmd.com/read/28097239/metastasis-regulation-by-ppard-expression-in-cancer-cells
#2
Xiangsheng Zuo, Weiguo Xu, Min Xu, Rui Tian, Micheline J Moussalli, Fei Mao, Xiaofeng Zheng, Jing Wang, Jeffrey S Morris, Mihai Gagea, Cathy Eng, Scott Kopetz, Dipen M Maru, Asif Rashid, Russell Broaddus, Daoyan Wei, Mien-Chie Hung, Anil K Sood, Imad Shureiqi
Peroxisome proliferator-activated receptor-δ (PPARD) is upregulated in many major human cancers, but the role that its expression in cancer cells has in metastasis remains poorly understood. Here, we show that specific PPARD downregulation or genetic deletion of PPARD in cancer cells significantly repressed metastasis in various cancer models in vivo. Mechanistically, PPARD promoted angiogenesis via interleukin 8 in vivo and in vitro. Analysis of transcriptome profiling of HCT116 colon cancer cells with or without genetic deletion of PPARD and gene expression patterns in The Cancer Genome Atlas colorectal adenocarcinoma database identified novel pro-metastatic genes (GJA1, VIM, SPARC, STC1, SNCG) as PPARD targets...
January 12, 2017: JCI Insight
https://www.readbyqxmd.com/read/28094194/mabp1-as-a-novel-antibody-treatment-for-advanced-colorectal-cancer-a-randomised-double-blind-placebo-controlled-phase-3-study
#3
Tamas Hickish, Thierry Andre, Lucjan Wyrwicz, Mark Saunders, Tomasz Sarosiek, Judit Kocsis, Radim Nemecek, Wojciech Rogowski, Krzysztof Lesniewski-Kmak, Lubos Petruzelka, Ron N Apte, Prasant Mohanty, Michael Stecher, John Simard, Aimery de Gramont
BACKGROUND: MABp1, an antibody that targets interleukin 1α, has been associated with antitumour activity and relief of debilitating symptoms in patients with advanced colorectal cancer. We sought to establish the effect of MABp1 with a new primary endpoint in patients with advanced colorectal cancer. METHODS: Eligible patients for the double-blind phase of this ongoing, placebo-controlled, randomised, phase 3 trial, had metastatic or unresectable disease, Eastern Cooperative Oncology Group performance status score 1 or 2, systemic inflammation, weight loss, and other disease-related morbidities associated with poor prognosis, and were refractory to oxaliplatin and irinotecan...
January 13, 2017: Lancet Oncology
https://www.readbyqxmd.com/read/28092401/randomized-clinical-trial-of-preoperative-oral-versus-intravenous-iron-in-anaemic-patients-with-colorectal-cancer
#4
B D Keeler, J A Simpson, O Ng, H Padmanabhan, M J Brookes, A G Acheson
BACKGROUND: Treatment of preoperative anaemia is recommended as part of patient blood management, aiming to minimize perioperative allogeneic red blood cell transfusion. No clear evidence exists outlining which treatment modality should be used in patients with colorectal cancer. The study aimed to compare the efficacy of preoperative intravenous and oral iron in reducing blood transfusion use in anaemic patients undergoing elective colorectal cancer surgery. METHODS: Anaemic patients with non-metastatic colorectal adenocarcinoma were recruited at least 2 weeks before surgery and randomized to receive oral (ferrous sulphate) or intravenous (ferric carboxymaltose) iron...
January 16, 2017: British Journal of Surgery
https://www.readbyqxmd.com/read/28089833/rufy3-promotes-metastasis-through-epithelial-mesenchymal-transition-in-colorectal-cancer
#5
Ruyi Xie, Jing Wang, Weimei Tang, Yueqiao Li, Ying Peng, Hui Zhang, Guangnan Liu, Xiaoting Huang, Jinjun Zhao, Aimin Li, Wei Gong, Ye Chen, Yuexin Ren, Yadong Wang, Guoxin Li, Side Liu, Jide Wang
Rufy3 is a RUN domain-containing protein that has been associated with gastric cancers; however, the role of Rufy3 in the progression of colorectal cancer (CRC) remains unknown. We demonstrated that Rufy3 expression was higher in 11/12 fresh CRC tissues than in adjacent normal tissues. Rufy3 induced elevated expression and transactivity of four major oncogenes in CRC. Moreover, siRNA-mediated repression of Rufy3 induced G0/G1 cell cycle arrest, and Rufy3 overexpression enhanced CRC cell proliferation in vitro and in vivo...
January 12, 2017: Cancer Letters
https://www.readbyqxmd.com/read/28088387/sirt2-mediated-antitumour-effects-of-shikonin-on-metastatic-colorectal-cancer
#6
Li-Li Zhang, Lin Zhan, Yong-Dong Jin, Zhen-Li Min, Can Wei, Qiang Wang, Ya-Jun Chen, Qing-Ming Wu, Xia-Min Hu, Qiong Yuan
SIRT2 is involved in the development of a variety of cancers. Shikonin is a natural compound that is known to have antitumour effects. This study aims to assess the effects of shikonin on the development and metastatic progression of colorectal cancer (CRC) through regulation of SIRT2 expression and whether this effect is related to the phosphorylation of extracellular signal-regulated kinases (ERKs). The results demonstrated that SIRT2 is downregulated in CRC biopsy samples (n = 31) compared with the adjacent non-cancerous tissues (ANCT, n = 26)...
January 11, 2017: European Journal of Pharmacology
https://www.readbyqxmd.com/read/28088224/clinical-analysis-of-krukenberg-tumours-in-patients-with-colorectal-cancer-a-review-of-57-cases
#7
K Y Xu, H Gao, Z J Lian, L Ding, M Li, J Gu
BACKGROUND: A Krukenberg tumour (KT) is defined as an ovarian metastasis from a gastrointestinal adenocarcinoma and suggests a terminal condition. This study aimed to identify the prognostic factors affecting the survival of patients with KTs of colorectal origin who receive cytoreductive surgery. METHODS: Medical records of patients who had received cytoreductive surgery and had been pathologically diagnosed with KT of colorectal origin in two centres were reviewed...
January 14, 2017: World Journal of Surgical Oncology
https://www.readbyqxmd.com/read/28088201/anti-allodynic-effect-of-buja-in-a-rat-model-of-oxaliplatin-induced-peripheral-neuropathy-via-spinal-astrocytes-and-pro-inflammatory-cytokines-suppression
#8
Yongjae Jung, Ji Hwan Lee, Woojin Kim, Sang Hyub Yoon, Sun Kwang Kim
BACKGROUND: Oxaliplatin, a widely used anticancer drug against metastatic colorectal cancer, can induce acute peripheral neuropathy, which is characterized by cold and mechanical allodynia. Activation of glial cells (e.g. astrocytes and microglia) and increase of pro-inflammatory cytokines (e.g. IL-1β and TNF-α) in the spinal cord play a crucial role in the pathogenesis of neuropathic pain. Our previous study demonstrated that Gyejigachulbu-Tang (GBT), a herbal complex formula, alleviates oxaliplatin-induced neuropathic pain in rats by suppressing spinal glial activation...
January 14, 2017: BMC Complementary and Alternative Medicine
https://www.readbyqxmd.com/read/28081548/serum-ldh-predicts-benefit-from-bevacizumab-beyond-progression-in-metastatic-colorectal-cancer
#9
Federica Marmorino, Lisa Salvatore, Cecilia Barbara, Giacomo Allegrini, Lorenzo Antonuzzo, Gianluca Masi, Fotios Loupakis, Beatrice Borelli, Silvana Chiara, Maria Chiara Banzi, Emanuela Miraglio, Domenico Amoroso, Francesco Dargenio, Andrea Bonetti, Angelo Martignetti, Myriam Paris, Daniela Tomcikova, Luca Boni, Alfredo Falcone, Chiara Cremolini
BACKGROUND: Different antiangiogenics are currently indicated in the second-line treatment of metastatic colorectal cancer (mCRC), following a first-line bevacizumab-containing treatment. The magnitude of benefit is limited, but no predictors of benefit have been identified. METHODS: A total of 184 mCRC patients progressing to a first-line bevacizumab-containing treatment were randomised in the BEBYP study to continue or not the antiangiogenic in combination with a second-line chemotherapy...
January 12, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28079003/colorectal-cancer-chemotherapy-the-evolution-of-treatment-and-new-approaches
#10
Rachel M McQuade, Vanesa Stojanovska, Joel C Bornstein, Kulmira Nurgali
Colorectal cancer (CRC) is one the greatest contributors to cancer related mortality. Although 5 year survival rate for patients at the early stage of CRC (stages I and II) is above 60%, more than 50% of patients are diagnosed at or beyond stage III when distant metastasis has already occurred, in which case 5 year survival rate drops to 10%. Chemotherapeutic intervention coupled with surgery is the backbone of metastatic CRC treatment and the only means of enhanced survival. For decades following its discovery, an antimetabolite 5-fluorouracil (5-FU) was the only chemotherapeutic agent available to successfully improve 12 month survival in CRC patients...
January 11, 2017: Current Medicinal Chemistry
https://www.readbyqxmd.com/read/28078982/phytochemicals-a-novel-and-prominent-source-of-anti-cancer-drugs-against-colorectal-cancer
#11
Ravikiran Mahadevappa, Hang Fai Kwok
Colorectal cancer (CRC) is a malignant disease whose incidence and mortality rates are greatly influenced by environmental factors. Under-treatment of CRC such as a poor diagnostic evaluation, less aggressive surgery, less intensive chemotherapy results in metastasizing of the primary tumor cells and recurrence of cancer. Prolonged chemotherapy treatment against cancer is hazardous to the patients, which also limits its use in cancer therapy. Current research in developing a novel anti-cancer agent, direct towards finding a better anti-metastatic and an anti-invasive drug with reduced side effects...
January 12, 2017: Combinatorial Chemistry & High Throughput Screening
https://www.readbyqxmd.com/read/28078133/successful-hepatectomy-for-metastatic-squamous-cell-carcinoma-of-the-anal-canal-a-case-report
#12
Tercia Tarciane Sousa, Bruna do Nascimento Santos, Marcos Belotto, Renata D'Alpino Peixoto
Despite rare, metastatic anal carcinoma confers a poor prognosis. Systemic chemotherapy is the mainstay of treatment for advanced disease while the role of biologics and/or surgical resection of metastatic disease are anecdotal. Compared to isolated liver colorectal or neuroendocrine cancer liver metastases, there is far less experience with resection or nonsurgical local ablative procedures for patients with metastatic anal carcinoma to the liver. We report the case of a 67-year-old woman with metastatic anal carcinoma to the liver who was successfully treated with liver resection and remains free of relapse more than one year later...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28078118/less-than-12-lymph-nodes-in-the-surgical-specimen-after-neoadjuvant-chemo-radiotherapy-an-indicator-of-tumor-regression-in-locally-advanced-rectal-cancer
#13
Jaiprakash Gurawalia, Kapil Dev, Sandeep P Nayak, Vishnu Kurpad, Arun Pandey
BACKGROUND: The number of lymph node retrieved in the surgical specimen is important for tumor staging and has paramount impact on prognosis in colorectal cancer and imitates the adequacy of lymph node surgical clearance. The paucity of lymph node yields in patients undergoing resection after preoperative chemo radiotherapy (CRT) in rectal cancer has seen. Lower total number of lymph nodes in the total mesoractal excision (TME) specimen after CRT, could a marker of better tumor response...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28078116/pretreatment-tumor-volume-as-a-prognostic-factor-in-metastatic-colorectal-cancer-treated-with-selective-internal-radiation-to-the-liver-using-yttrium-90-resin-microspheres
#14
Neha Bhooshan, Navesh K Sharma, Shahed Badiyan, Adeel Kaiser, Fred M Moeslein, Young Kwok, Pradip P Amin, Svetlana Kudryasheva, Michael D Chuong
BACKGROUND: Yttrium-90 ((90)Y)-resin microspheres can prolong intrahepatic disease control and improve overall survival (OS) in patients with metastatic colorectal cancer (CRC). Prognostic factors for improved outcomes in patients undergoing selective internal radiation therapy (SIRT) have been studied, but the relationship between pre-SIRT liver tumor volume and outcomes has not well described. METHODS: We retrospectively reviewed the records of patients with metastatic CRC who were treated at our institution with (90)Y-resin microspheres...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28078110/radioembolization-with-90-y-glass-microspheres-for-the-treatment-of-unresectable-metastatic-liver-disease-from-chemotherapy-refractory-gastrointestinal-cancers-final-report-of-a-prospective-pilot-study
#15
Nicholas Fidelman, Robert K Kerlan, Randall A Hawkins, Miguel Pampaloni, Andrew G Taylor, Maureen P Kohi, K Pallav Kolli, Chloe E Atreya, Emily K Bergsland, R Kate Kelley, Andrew H Ko, W Michael Korn, Katherine Van Loon, Ryan M McWhirter, Jennifer Luan, Curt Johanson, Alan P Venook
BACKGROUND: This prospective pilot single-institution study was undertaken to document the feasibility, safety, and efficacy of radioembolization of liver-dominant metastatic gastrointestinal cancer using (90)Y glass microspheres. METHODS: Between June 2010 and October 2013, 42 adult patients (26 men, 16 women; median age 60 years) with metastatic chemotherapy-refractory unresectable colorectal (n=21), neuroendocrine (n=11), intrahepatic bile duct (n=7), pancreas (n=2), and esophageal (n=1) carcinomas underwent 60 lobar or segmental administrations of (90)Y glass microspheres...
December 2016: Journal of Gastrointestinal Oncology
https://www.readbyqxmd.com/read/28077117/topoisomerase-i-copy-number-alterations-as-biomarker-for-irinotecan-efficacy-in-metastatic-colorectal-cancer
#16
Jesper Andreas Palshof, Estrid Vilma Solyom Høgdall, Tim Svenstrup Poulsen, Dorte Linnemann, Benny Vittrup Jensen, Per Pfeiffer, Line Schmidt Tarpgaard, Nils Brünner, Jan Stenvang, Mette Yilmaz, Dorte Lisbet Nielsen
BACKGROUND: No biomarker exists to guide the optimal choice of chemotherapy for patients with metastatic colorectal cancer. We examined the copy numbers (CN) of topoisomerase I (TOP1) as well as the ratios of TOP1/CEN-20 and TOP1/CEN-2 as biomarkers for irinotecan efficacy in patients with metastatic colorectal cancer. METHODS: From a national cohort, we identified 163 patients treated every third week with irinotecan 350 mg/m(2) as second-line therapy. Among these 108 were eligible for analyses and thus entered the study...
January 11, 2017: BMC Cancer
https://www.readbyqxmd.com/read/28075526/cetuximab-strongly-enhances-immune-cell-infiltration-into-liver-metastatic-sites-in-colorectal-cancer
#17
Yuka Inoue, Shoichi Hazama, Nobuaki Suzuki, Yukio Tokumitsu, Shinsuke Kanekiyo, Shinobu Tomochika, Ryouichi Tsunedomi, Yoshihiro Tokuhisa, Michihisa Iida, Kazuhiko Sakamoto, Shigeru Takeda, Tomio Ueno, Shigefumi Yoshino, Hiroaki Nagano
Cetuximab has activity against colorectal cancers. Recent studies demonstrated that cetuximab induces antibody-dependent cell-mediated cytotoxicity via immune cells, and a new immune-related mechanism of inducing immunogenic cell death. This study aimed to evaluate the immune responses induced by cetuximab in tumor microenvironments at liver metastasis sites of metastatic colorectal cancer patients. We assessed immune cell infiltration in the liver metastatic sites of 53 colorectal cancer patients. These patients were divided into three groups according to the treatment before operation: chemotherapy with cetuximab, chemotherapy without cetuximab, and no chemotherapy...
January 11, 2017: Cancer Science
https://www.readbyqxmd.com/read/28075454/expression-of-glia-maturation-factor-%C3%AE-is-associated-with-colorectal-cancer-metastasis-and-its-downregulation-suppresses-colorectal-cancer-cell-migration-and-invasion-in-vitro
#18
Huili Wang, Zhijiang Chen, Hongen Chang, Xiaoping Mu, Wenyu Deng, Zhaohu Yuan, Fang Yao, Yan Liu, Rongjia Mai, Bingyi Wu
Glia maturation factor γ (GMFG) functions to reorganize the actin cytoskeleton and appears to play a causative role in cell migration and adherence. The present study assessed GMFG expression in colorectal cancer cells and tissue specimens and then explored the role of GMFG in colorectal cancer progression in vitro. GMFG protein was highly expressed in colorectal cancer tissues and a metastatic colon cancer cell line. Knockdown of GMFG expression using GMFG siRNA or anti-GMFG antibody decreased the capacity of colon cancer LoVo cell migration and invasion in vitro, while recombinant GMFG treatment induced LoVo cell migration...
February 2017: Oncology Reports
https://www.readbyqxmd.com/read/28074472/cost-evaluation-of-irinotecan-related-toxicities-associated-with-the-ugt1a1-28-patient-genotype
#19
R Roncato, E Cecchin, M Montico, E De Mattia, L Giodini, A Buonadonna, V Solfrini, F Innocenti, G Toffoli
The adoption of a pre-emptive UGT1A1*28 genotyping to increase irinotecan safety in clinical practice is still limited. This is the first actual study of costs associated to the management of irinotecan-related toxicity, and their association with UGT1A1*28 genotype. A retrospective analysis of the cost of toxicity management was conducted on 243 metastatic colorectal cancer patients enrolled in a clinical trial and treated with standard of care FOLFIRI. The mean predicted cost per patient was higher for *28/*28 (4,886€), versus *1/*1 (812€), (regression coefficient 1...
January 11, 2017: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/28073899/paper-based-microrna-expression-profiling-from-plasma-and-circulating-tumor-cells
#20
Sai Mun Leong, Karen Mei-Ling Tan, Hui Wen Chua, Mo-Chao Huang, Wai Chye Cheong, Mo-Huang Li, Steven Tucker, Evelyn Siew-Chuan Koay
BACKGROUND: Molecular characterization of circulating tumor cells (CTCs) holds great promise for monitoring metastatic progression and characterizing metastatic disease. However, leukocyte and red blood cell contamination of routinely isolated CTCs makes CTC-specific molecular characterization extremely challenging. METHODS: Here we report the use of a paper-based medium for efficient extraction of microRNAs (miRNAs) from limited amounts of biological samples such as rare CTCs harvested from cancer patient blood...
January 10, 2017: Clinical Chemistry
keyword
keyword
27670
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"